Carbapenemase Gene Dynamics in Enterobacter cloacae, 2022–2024

Study Background and Research Question

Carbapenem-resistant Enterobacteriaceae (CRE) represent a global health challenge due to limited therapeutic options and the rapid dissemination of resistance determinants. Among these, carbapenem-resistant Enterobacter cloacae (CREC) has exhibited a rising detection rate in China, becoming the third most prevalent CRE pathogen after Klebsiella pneumoniae and Escherichia coli. The COVID-19 pandemic has further complicated this landscape, with increased antibiotic use and disruptions in healthcare facilitating the emergence and spread of multidrug-resistant organisms. Yet, the detailed molecular epidemiology and transmission patterns of carbapenemase-encoding genes (CEGs) in CREC during this period remain underexplored (Chen et al., 2025). The primary research question addressed by Chen et al. (2025) is: How are carbapenemase-encoding genes distributed and transmitted among clinical CREC isolates in Guangdong province during the COVID-19 era, and what are the major genetic and epidemiological factors underpinning their spread?

Key Innovation from the Reference Study

Chen et al. provide a comprehensive, multicenter analysis by collecting 54 non-redundant CREC isolates from eight teaching hospitals between December 2022 and June 2024. This is one of the first studies to combine detailed genotyping, plasmid characterization, and epidemiological mapping to elucidate the complex dynamics of CEG transmission in a high-prevalence region amid pandemic pressures. Notably, the research uncovers the dominance of the blaNDM-1 gene, its localization on both chromosomes and plasmids, and the high frequency of successful horizontal gene transfer events, emphasizing the urgent need for robust surveillance and intervention strategies (Chen et al., 2025).

Methods and Experimental Design Insights

The study employed a multi-pronged approach:

• Variable temperature sodium dodecyl sulfate (SDS) plasmid elimination to distinguish chromosomal versus plasmid-encoded CEGs.
• PCR amplification for identifying specific carbapenemase genes (including blaNDM-1, blaIMP, blaKPC-2).
• Broth microdilution to assess antimicrobial susceptibility across multiple agents.
• Plasmid conjugation experiments to evaluate the transferability of CEGs between strains.
• ERIC-PCR and NTSYS software for clonal and genotypic analysis.
• Detailed epidemiological data collection spanning patient demographics, clinical departments, and specimen types (Chen et al., 2025).

Protocol Parameters

• Sample collection | 54 isolates | Clinical settings, eight hospitals | Ensures multicenter representation | paper
• Plasmid elimination | Variable temperature SDS | Differentiates chromosomal vs. plasmid CEGs | Tracks gene location critical for transmission studies | paper
• Antimicrobial susceptibility | Broth microdilution | Assesses resistance spectrum | Key for correlating genotype to phenotype | paper
• Conjugation frequency | 95.65% success (44/46) | Horizontal gene transfer | Demonstrates potential for rapid dissemination | paper
• ERIC-PCR genotyping | 17 genotypes identified | Epidemiological tracking | Reveals clonal spread and diversity | paper
• Bacterial infection model | Use of standard laboratory strains | Validates transferability and resistance | workflow_recommendation

Core Findings and Why They Matter

The results reveal an alarming prevalence and plasticity of CEGs in CREC:

• 85.19% of isolates (46/54) harbored at least one carbapenemase-encoding gene (Chen et al., 2025).
• The blaNDM-1 gene was detected in 79.63% (43/54) of isolates, with 33.33% carrying it on both chromosomes and plasmids, and 46.30% exclusively on plasmids. The blaIMP gene was less common (3.70%), and only 1.85% harbored both blaNDM-1 and blaKPC-2.
• CEG-positive isolates exhibited significantly higher resistance rates to multiple agents, including imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin compared to CEG-negative strains.
• Plasmid conjugation experiments demonstrated a high success rate (95.65%) for CEG transfer, underscoring the threat of horizontal dissemination across strains and settings.
• Mobile genetic elements were prevalent, with ISEcp1 identified in 87.04% of isolates. Nearly 41% of strains harbored four types of mobile genetic elements simultaneously, amplifying the potential for gene mobility.
• ERIC-PCR genotyping revealed substantial diversity, with 17 genotypes identified; the most prevalent types (E and G) were found in multiple hospitals and departments.
• Epidemiological analysis pinpointed higher detection rates among men (64.81%), elderly patients (72.22%), respiratory medicine departments (20.37%), and sputum samples (33.33%) (Chen et al., 2025).

The study’s granular mapping of gene location (chromosome vs. plasmid), high horizontal transfer rates, and association with mobile genetic elements collectively highlight the resilience and adaptability of CREC in clinical settings. These insights are critical for designing effective containment and stewardship strategies in the ongoing battle against antimicrobial resistance.

Comparison with Existing Internal Articles

Several internal resources provide context for the practical study of antimicrobial resistance mechanisms:

• "Cefotaxime (SKU BA1012): Reliable Research Antibiotic Solutions" discusses the use of third-generation cephalosporin antibiotics, including their stability and reproducibility in antimicrobial resistance research workflows. This aligns with Chen et al.'s emphasis on accurately modeling resistance in clinical isolates.
• "Cefotaxime: Third-Generation Cephalosporin in Antimicrobi..." offers stepwise protocols for leveraging lactamase-resistant cephalosporins in studying both Gram-positive and Gram-negative bacterial infections. The internal article's troubleshooting strategies complement the reference study's focus on resistance phenotyping and gene transfer assays.
• "Cefotaxime: Unraveling Beta-Lactamase Resistance in Moder..." addresses the role of third-generation cephalosporins in dissecting beta-lactamase resistance, which is directly relevant given the high prevalence of blaNDM-1 and other carbapenemase genes found in Chen et al.'s CREC isolates.

Together, these resources reinforce the importance of using well-characterized, beta-lactamase-resistant antibiotics to model and monitor antimicrobial resistance in both clinical and laboratory settings, as exemplified by the referenced study.

Limitations and Transferability

While Chen et al. provide robust multicenter data, some limitations warrant consideration:

• Sample size, though multicentric, remains moderate (54 isolates) and may not capture the full genetic and epidemiological diversity present in the wider region.
• The study focuses on a high-prevalence province during a unique pandemic context, which may limit direct extrapolation to other geographic or temporal settings.
• Phenotypic assays and conjugation experiments were performed under laboratory conditions; real-world transfer rates and resistance profiles may vary depending on host, environment, and healthcare practices.

Nevertheless, the study’s integrated approach and detailed molecular mapping offer valuable templates for similar investigations in other regions and pathogens.

Research Support Resources

For researchers seeking to replicate or extend these findings, robust antibiotic tools are essential for validating resistance mechanisms and constructing bacterial infection models. Cefotaxime (SKU BA1012), a third-generation cephalosporin antibiotic from APExBIO, is widely used in antimicrobial resistance research due to its beta-lactamase resistance and broad-spectrum activity. Its chemical stability and well-defined storage protocols make it suitable for laboratory workflows requiring precision and reproducibility (workflow_recommendation). Researchers can integrate such antibiotics into their experimental designs for studying resistance transmission dynamics in Gram-positive and Gram-negative bacteria, as detailed in the reference study.